Next Article in Journal
Neural Indicators of Fatigue in Chronic Diseases: A Systematic Review of MRI Studies
Previous Article in Journal
Open-Ended Coaxial Probe Technique for Dielectric Measurement of Biological Tissues: Challenges and Common Practices
Previous Article in Special Issue
Multimodal Discrimination between Normal Aging, Mild Cognitive Impairment and Alzheimer’s Disease and Prediction of Cognitive Decline
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessArticle
Diagnostics 2018, 8(2), 41; https://doi.org/10.3390/diagnostics8020041

Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease

1
Department of Chemistry, Lakehead University, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada
2
Thunder Bay Regional Health Research Institute, 980 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada
3
Thunder Bay Regional Health Sciences Centre, 980 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada
4
Northern Ontario School of Medicine, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada
*
Author to whom correspondence should be addressed.
Received: 3 May 2018 / Revised: 28 May 2018 / Accepted: 5 June 2018 / Published: 6 June 2018
(This article belongs to the Special Issue Alzheimer's Disease Imaging Biomarkers)
Full-Text   |   PDF [1875 KB, uploaded 6 June 2018]   |  

Abstract

Biomarkers have the potential to aid in the study of Alzheimer’s disease (AD); unfortunately, AD biomarker values often have a high degree of overlap between healthy and AD individuals. This study investigates the potential utility of a series of novel AD biomarkers, the sixty second 129Xe retention time, and the xenon washout parameter, based on the washout of hyperpolarized 129Xe from the brain of AD participants following inhalation. The xenon washout parameter is influenced by cerebral perfusion, T1 relaxation of xenon, and the xenon partition coefficient, all factors influenced by AD. Participants with AD (n = 4) and healthy volunteers (n = 4) were imaged using hyperpolarized 129Xe magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) to determine the amount of retained xenon in the brain. At 60 s after the breath hold, AD patients retained significantly higher amounts of 129Xe compared to healthy controls. Data was fit to a pharmacokinetic model and the xenon washout parameter was extracted. Xenon washout in white and grey matter occurs at a slower rate in Alzheimer’s participants (129Xe half-life time of 42 s and 43 s, respectively) relative to controls (20 s and 16 s, respectively). Following larger scale clinical trials for validation, the xenon washout parameter has the potential to become a useful biomarker for the support of AD diagnosis. View Full-Text
Keywords: hyperpolarized gas MRI; xenon; gas retention; Alzheimer’s disease; wash out; vascular hyperpolarized gas MRI; xenon; gas retention; Alzheimer’s disease; wash out; vascular
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Hane, F.T.; Li, T.; Plata, J.-A.; Hassan, A.; Granberg, K.; Albert, M.S. Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease. Diagnostics 2018, 8, 41.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top